scispace - formally typeset
K

Kenneth O. Schowengerdt

Researcher at Cardinal Glennon Children's Hospital

Publications -  42
Citations -  1038

Kenneth O. Schowengerdt is an academic researcher from Cardinal Glennon Children's Hospital. The author has contributed to research in topics: Transplantation & Heart transplantation. The author has an hindex of 17, co-authored 40 publications receiving 974 citations. Previous affiliations of Kenneth O. Schowengerdt include Baylor College of Medicine & University of Florida.

Papers
More filters
Journal ArticleDOI

Association of Parvovirus B19 Genome in Children With Myocarditis and Cardiac Allograft Rejection Diagnosis Using the Polymerase Chain Reaction

TL;DR: Parvovirus genome identified through PCR analysis of cardiac tissue in the clinical setting of myocarditis and cardiac allograft rejection may be a potential contributor to cardiac transplant rejection.
Journal Article

Restrictive cardiomyopathies in childhood. Etiologies and natural history.

TL;DR: In conclusion, restrictive cardiomyopathy in childhood is commonly idiopathic or associated with cardiac hypertrophy, and the prognosis is poor; therefore, transplantation should be considered early.
Journal Article

Infection after pediatric heart transplantation: Results of a multiinstitutional study

TL;DR: Although most infections in pediatric heart transplant recipients are successfully treated, infection remains an important cause of posttransplantation morbidity and death, especially in infants.
Journal Article

Diagnosis, surveillance, and epidemiologic evaluation of viral infections in pediatric cardiac transplant recipients with the use of the polymerase chain reaction.

TL;DR: Polymerase chain reactions may be used as a rapid and sensitive method to evaluate postoperative viral infections in heart transplant recipients, especially in those with late-onset rejection or chronic rejection.
Journal ArticleDOI

Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients

TL;DR: Pravastatin therapy is effective and safe when used in pediatric and adolescent cardiac transplant recipients and long-term studies are required to evaluate the effect of pravastin therapy on the incidence of accelerated coronary atherosclerosis in this population.